Abstract Body

Background: FEM-PrEP – a clinical trial of daily emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for HIV prevention – was unable to determine the effectiveness of FTC/TDF among women in sub-Saharan Africa due to low study product adherence. We implemented a follow-up study to identify factors that influenced participants’ non-adherence and reasons for participation. Methodology: We conducted qualitative, semi-structured interviews (SSIs) (n=88) and quantitative audio computer-assisted self-interviews (ACASI) (n=224) with FEM-PrEP participants in Bondo, Kenya, and Pretoria, South Africa. SSI participants were purposefully sampled to represent a range of drug concentrations. The ACASI questionnaire was completed by most SSI participants (n=86), a randomly selected group of participants assigned placebo (n=50), and a separate group interviewed about risk perceptions (n=88). We used thematic analysis and descriptive statistics to analyze the qualitative and quantitative data, respectively. Ickovics’ and Meisler’s conceptual framework on adherence was used to better understand behavioral and contextual factors surrounding adherence. Results: Table 1 lists factors influencing non-adherence, as reported in ACASI, for four of the five categories of the framework. Reasons for trial participation may be indirectly related to the fifth category – clinical setting (e.g., services): 93% of participants said they participated in FEM-PrEP because of indirect benefits (e.g., medical care). In the SSIs, participants frequently mentioned several individual and regimen-related factors as reasons other participants were non-adherent, including lack of support or discouragement from others, unknown effectiveness of FTC/TDF and unknown pill randomization, perceptions of low or variable HIV risk, large pill size, concerns about side effects, and the uncommon practice of taking pills when not sick. Conclusions: Use of an investigational drug was a prominent concern among participants from both sites, although especially in Pretoria. Unacceptability of a daily pill as PrEP for some participants, particularly among women in Pretoria, and negative influences from others also influenced adherence within the context of a clinical trial. The trial’s indirect benefits may have encouraged women who were not interested in taking the study product to enroll. Alternative study designs/procedures and enhanced community engagement paradigms may be needed in future studies.